Helen is Director of Translational Sciences of Elixiron Immunotherapeutics. She provides translational leadership to link drug discovery to unmet medical needs for Elixiron's immuno-oncology projects. Helen is an immunologist with research experiences in the regulations of T cell exhaustion and innate immunity. She has published several peer-reviewed manuscripts in Immunology’s leading journals including Immunity and Journal of Immunology. Previously, Helen served as R&D Manager at Eusol Biotech Co., Ltd., where she was responsible for establishing immunological assays to support drug development. Prior to Eusol, Helen was a Research Fellow of Protein Engineering Group at Development Center for Biotechnology (DCB). There, she participated in the preclinical development of therapeutics biologics. In addition to her former role in DCB, she held two research positions at Meridigen Biotech Co., Ltd. and UnicoCell Biomed Co., Ltd. Helen earned her Ph.D. in Immunology from National Yang-Ming University and completed her postdoctoral training in the Institute of Molecular Biology at Academia Sinica.